Focused On-demand Library for ATP-dependent RNA helicase DHX30

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

DEAH box protein 30

Alternative UPACC:

Q7L2E3; A8K5F1; O94965; Q7Z753; Q96CH4; Q9NUQ0


ATP-dependent RNA helicase DHX30, also known as DEAH box protein 30, is pivotal in RNA processing and mitochondrial function. It acts as an RNA-dependent helicase, crucial for the assembly of the mitochondrial large ribosomal subunit, enhancing mitochondrial protein synthesis. DHX30's role extends to the regulation of the zinc-finger antiviral protein ZC3HAV1 and association with mitochondrial DNA, underpinning its importance in cellular antiviral responses and mitochondrial integrity.

Therapeutic significance:

DHX30's involvement in neurodevelopmental disorder with variable motor and language impairment highlights its therapeutic potential. Targeting DHX30 could lead to novel interventions for this disorder, emphasizing the importance of understanding its biological mechanisms for developing targeted therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.